Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept Combination Therapy in Lower Risk Myelodysplasia (MyeloMATCH Substudy)
NCT07463820Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of luspatercept in myelodysplastic syndrome (MDS), anemia, sponsored by National Cancer Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT07463820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463820.